Risk Factors for Infusion Reactions Associated With Rituximab Therapy
Cancer Diagnosis & Prognosis · 01.09.2025 · 5 (5) · 552-556
DOI: 10.21873/cdp.10469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.09.2025. Verfasst von Takahiro Amemiya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/Aim: Although rituximab is used to treat a range of diseases, the high frequency of rituximab-associated infusion reactions (IRs) poses a clinical challenge. This study aimed to identify pre-treatment risk factors associated with rituximab-induced IRs using retrospective patient data. Patients and Methods: We retrospectively analyzed the medical records of patients treated with rituximab. Data were compared between patients with and without IRs.
Results
Among the variables assessed, an elevated C-reactive protein (CRP) level prior to rituximab administration was significantly associated with IR occurrence (odds ratio=2.591; 95% confidence interval=1.160-5.791; p=0.020).
Conclusion
Elevated pre-medication levels of CRP are a significant risk factor associated with the use of rituximab, thereby highlighting the need for close monitoring of patients receiving rituximab who present with elevated CRP levels prior to the initiation of therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.
- Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Zitieren
APA
Amemiya, T., & Suzuki, H. (2025). Risk Factors for Infusion Reactions Associated With Rituximab Therapy. Cancer Diagnosis & Prognosis, 5(5), 552-556. https://doi.org/10.21873/cdp.10469
Vancouver
Amemiya T, Suzuki H. Risk Factors for Infusion Reactions Associated With Rituximab Therapy. Cancer Diagnosis & Prognosis. 2025;5(5):552-556. doi:10.21873/cdp.10469
BibTeX
@article{Amemiya2025,
author = {Amemiya, Takahiro and Suzuki, Hiroshi},
title = {Risk Factors for Infusion Reactions Associated With Rituximab Therapy},
journal = {Cancer Diagnosis & Prognosis},
year = {2025},
volume = {5},
number = {5},
pages = {552--556},
doi = {10.21873/cdp.10469}
}
EUVIMED